InVivo Therapeutics Names Veteran Biomaterials Expert Bill D'Agostino as Senior Director of Manufacturing & Engineering
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 28, 2012--InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma, today announced the appointment of Bill D'Agostino as Senior Director of Manufacturing & Engineering.
An executive leader focused on rapid market growth, Mr. D'Agostino joins InVivo following fifteen years at Covidien and, most recently, seven years at Angiotech Pharmaceuticals as Vice President, Engineering. In his career to date, Mr. D’Agostino has launched more than 100 new polymer products including families of biodegradable sutures.
Mr. D'Agostino is a seasoned professional in medical devices and pharmaceutical excelling in all aspects of Research & Development, Engineering, GMP Operations and Quality Assurance, and has a wealth of expertise on technologies such as hydrogels and biodegradable sutures. He has worked on every stage of the product life cycle including end-user requirements, risk management, feasibility, development, quality systems, design verification, pilot manufacturing, validations, regulatory approvals, clinical field testing, full manufacturing, product launch, marketing and post-market surveillance.
Said InVivo CEO Frank Reynolds, “Bill has a unique history and expertise in getting products to market. I am confident that his wide-ranging experience with all aspects of commercializing medical devices and with FDA submissions will play a pivotal role as we plan to begin a clinical trial for “First in Man” use of biopolymer scaffolding to treat acute SCI.” “There is no time like the present for driving innovation to a higher level, and InVivo Therapeutics is just the company to do it considering the multiple products in our pipeline and the significant unmet medical needs in neurotrauma,” said Mr. D’Agostino.
Mr. D'Agostino is a licensed Professional Engineer (PE), with a Bachelor of Science degree in Chemical Engineering & Materials Engineering from the University of Connecticut. He received his MBA with the highest honors from the University of Dallas.
About InVivo Therapeutics InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious 2011 David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company’s products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company’s products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2011 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.CONTACT: InVivo Therapeutics Holdings Corp.
Lauren Mitarotondo (617) 863-5510 firstname.lastname@example.org KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES OTHER HEALTH MANUFACTURING ENGINEERING GENERAL HEALTH SOURCE: InVivo Therapeutics Holdings Corp. Copyright Business Wire 2012 PUB: 09/28/2012 06:00 AM/DISC: 09/28/2012 06:00 AM http://www.businesswire.com/news/home/20120928005078/